

Original claims 1 – 34:

- 1 An improved method of hormonal treatment of breast cancer and said
hormonal treatment comprising of breast implants of anti-estrogens and
5 steroid hormones, or its synthetic derivatives in one or more slow release
formulations and permitting said drugs to be continuously released at near
constant rate directly to the breast for longer periods with minimal or no
systemic toxicity.
- 10 2 A method according to claim 1 further comprising release of said anti-
estrogen and hormonal compositions to the breast for extended periods by
diffusion and biodegradation from said breast implants in sufficient amounts
to saturate the binding sites for said drug compositions in the breast and to
exert their maximum tumor control activity.
- 15 3 A method of claim 1 wherein said implants comprising of hormonally
effective compositions selected from the anti-estrogen groups consisting of
tamoxifen, raloxifene and toremifene, and from the hormonal groups
consisting of progesterones and corticosteroids.
- 20 4 A method according to claim 1 wherein said prostatic implants of said drug
compositions are made as separate or in combination thereof.

5 The method of claim 1 wherein said breast implants are made as
biodegradable fused combinations of said therapeutic drug compositions and a
lipoid carrier and said fused implants containing a single or multiples of said
drug formulations for their slow release direct to breast.

5

6 A method according to claim 1 wherein said breast implants are made of
Silastic capsules containing said therapeutic drug compositions as separate or
in combination thereof for said formulation's slow release direct to breast.

10

7 The method of claim 1 wherein said breast implants are made as injectable
microcapsules prepared from biodegradable polymer and said microcapsules
containing said therapeutic drug compositions as separate or as in combination
thereof for injection to the breast as slow release implant.

15

8 The method of claim 7, wherein said prostatic implants are made as injectable
microcapsules prepared from biodegradable polymer and said microcapsules
containing said therapeutic drug compositions dispensed in sterile liquid
medium in sterile syringe for direct prostatic injection as slow release implant.

20

9 The method of claim 7, wherein said breast implants are made as injectable
microcapsules prepared from biodegradable polymer and said microcapsules
containing said therapeutic drug compositions dispensed in a mixture of sterile
liquid mediums like normal saline, a local anesthetic and ethanol in a sterile

syringe for direct injection to the breast as chelating slow release formulations when it comes in contact with breast tissue.

10 The method of claim 1 wherein said breast implants are selected from readily
5 available commercial pharmaceutical preparations of anti-estrogens steroid hormones or their derivatives and said implants containing a single or multiples of said drug formulations for their slow release direct to the breast.

11 An improved method of concomitant hormonal and radiation treatment of the
10 breast cancer and said hormonal treatment comprising of breast implants of anti-estrogens and steroid hormones in one or more slow release formulations and permitting said drugs to be continuously released at near constant rate directly to the breast during the radiation therapy and afterwards for longer periods.

15 12 An improved method of concomitant hormonal and radiation treatment of the breast cancer according to claim 11, wherein said continued slow release of hormonal composition directly to the breast during the interstitial radioactive seeds implants and afterwards for longer periods.

20 13 An improved method of concomitant hormonal and radiation treatment of breast cancer according to claim 11, wherein said hormonal implants to the

breast is performed concomitantly with the radioactive implants to improve cure and convenience to patient than when they are implanted separately.

5
14 An improved method of treating hormone dependent and hormone refractory breast cancer and its accessible metastasis by implanting combinations of hormones and anti-estrogens to said tumor sites for improved tumor control with lesser toxicity than by administering said hormonal compositions at higher doses by mouth, subcutaneous, intramuscular or intravenous routes and said hormone compositions containing in one or more slow release implant
10 formulations.

15 A method of claim 14, wherein said breast, subcutaneous or intramuscular hormonal implants methods comprising implanting single or synergetic combination of hormonally and cytotoxically effective compositions selected
15 from the anti-estrogen groups consisting of tamoxifen, raloxifene and toremifene and from the hormonal groups consisting of iodo-estradiol, progesterones, corticosteroids and they are fused with a lipid carrier or encapsulated in Silastic capsules or formulated as injectable microcapsules as suitable slow-release breast, subcutaneous or intramuscular implant.

20

16 A method of claim 14, wherein said slow-release breast implant of anti-estrogen and hormonal compositions for treating breast cancer and providing

minimum or no toxicity as compared to when said drug compositions are administered by oral routes daily.

17 A method of claim 14, wherein high concentrations of said drug composition to the breast is achieved by implanting said formulations directly to the breast and to derive the added beneficial effect from these breast implants on breast cancer by inhibiting the hypothalamic-pituitary LHRH, FSH and LH secretion by these composition's systemic contents.

18 Slow-release anti-cancer breast implants products for treatment of breast cancer and comprising of anti-estrogens and steroid hormones as fused with a lipoid carrier or as encapsulated in Silastic capsules or as injectable microcapsules and are suitable for breast implantation such that said hormonally and cytotoxically effective compositions are continuously released at relatively high constant rates to the breast.

19 The said products of claim 18 being further characterized by providing effective tumor control and having minimum or no systemic toxicity associated with said composition's breast implants than if they were daily administered orally for several years at much higher doses to achieve the same results.

20 Slow-release anti-cancer prostate implant product of claim 18, wherein said
single drug formulation is made from any one of the anti-estrogen drugs from
a group consisting of tamoxifen, raloxifene or toremifene and hormonal
compositions consisting of progesterone, androgens or prednisolone.

5

21 Slow-release anti-cancer breast implant product of claim 18, wherein said
synergetic two drugs formulations comprises of an anti-estrogen from the
groups of tamoxifen, raloxifene, or toremifene and a progesterone
composition selected from the group consisting of megestrol acetate,
10 medroxyprogesterone, norethindrone acetate or norgestrel or from the
corticosteroids groups, the prednisolone.

22 Slow-release anti-cancer breast implant product of claim 18, wherein said
synergetic three drugs formulations comprises of an anti-estrogen from the
15 groups of tamoxifen, raloxifene, or toremifene and a progesterone
composition selected from the group consisting of megestrol acetate,
medroxyprogesterone, norethindrone acetate norgestrel and from the
corticosteroids group prednisolone.

20 23 Anti-cancer products of claim 18, wherein said compositions comprising of
single or synergetic combination of hormonally and cytotoxically effective
amount of an anti-estrogen from the groups of tamoxifen, raloxifene, or
toremifene and a progesterone composition selected from the group consisting

of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone as fused with a lipid carrier suitable for prostatic implantation.

5 24 Anticancer products according to claim 18, wherein said single or synergetic
combination of hormonally and cytotoxically effective amounts of
formulations as fused with a lipid carrier suitable for breast implantation
such that said compositions are continuously released at relatively constant
rates to the breast for longer periods and the contents of said compositions
10 being kept in amounts effective to suppress tumor growth with minimum or
no systemic toxicity than if said drug compositions were administered daily
by oral routes at much higher doses to achieve the same results as by said low
dose breast implants.

15 25 Anticancer products of claim 18, wherein said single or synergetic
combinations of hormonally and cytotoxically effective amounts of an anti-
estrogen from the groups of tamoxifen, raloxifene, or toremifene and a
progesterone composition selected from the group consisting of megestrol
20 acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the
corticosteroids group prednisolone in same or separate slow release Silastic
capsules suitable for prostatic implantation.

26 Anticancer products according to claim 18, wherein said single or synergetic combination of hormonally and cytotoxically effective formulations as in slow release Silastic capsules suitable for breast implantation such that said compositions are continuously released at relatively constant rates for longer periods and with minimum or no systemic toxicity than if said drug compositions were frequently administered orally at much higher doses to achieve the same results as by said low dose breast implants.

27 Anticancer products according to claim 18, wherein said anti-cancer products comprising of single or synergetic combination of hormonally and cytotoxically effective amounts of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone in same or separate slow release injectable microcapsules suitable for breast implantation.

28 Anticancer products according to claim 27, wherein said single or synergetic combination of hormonally and cytotoxically effective amount of formulations as injectable microcapsules suitable for breast implantation such that said compositions are continuously released at relatively constant rates and the contents of said compositions being kept in amounts effective to suppress tumor growth with minimum or no systemic toxicity than if said drug

compositions were frequently administered orally at much higher doses to achieve the same results as by said low dose breast implants.

29 Anticancer products according to claim 18, wherein said implant products
5 comprising of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof and fused with a lipoid carrier.

10

30 Anti-cancer prostatic implant products according to claim 18, wherein said biodegradable breast implants comprising of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate,
15 medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof as injectable microcapsules.

31 Anti-cancer prostatic implant products of claim 18, wherein said breast
20 implants comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone

acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof in Silastic capsules.

32 A slow-release hormonal breast implant method and products comprising
5 single or synergetic combination of hormonally and cytotoxically effective compositions selected from the an anti-estrogen groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and they
10 are fused with a lipid carrier or encapsulated in Silastic capsules or formulated as injectable microcapsules as suitable slow-release breast implantation and implanting said products for the treatment of early and advanced stage breast cancers and as hormonal treatment combined with radiation.

15

33 A method and product of claim 32, wherein said hormone implant treatment of breast cancer is less-costly, less toxic and more convenient to the patient.

20

34 A method and product of claim 32, wherein said slow-release anti-estrogen implant treatment of the breast as hormonal prophylaxis against developing breast cancer by saturation of the breast tissue's binding sites for said anti-estrogens with high efficiency than by said anti-estrogen's daily oral administration at higher doses.

In the claims:

Clean version incorporating all changes

5 **Original Claims 1 – 17, 25, 33 and 34 are currently amended Claims 35 – 51,
52, 53 and 54**

Claims 18-24 and 26-32 are original claims

35 A method of minimal or no toxic primary hormonal treatment of breast cancer
10 about one thousand dollars of drug's cost for five years treatment as compared to
the present cost of about 20-35,000 dollars for similar five years treatment for
said hormonal treatment of breast cancer comprising of breast implants of anti-
estrogens and steroid hormones and their synthetic derivatives as fused with a
lipoid carrier or as encapsulated in Silastic capsules or as injectable
15 microcapsules which are suitable for breast implantation such that said
hormonally and cytotoxically effective compositions are continuously released at
rates of 50 to 100 μ g per day directly to the breast to saturate the estrogen and
steroid hormone binding sites in breast cancer to inhibit tumor growth and to
minimize the systemic toxicity caused by administration of said drugs by oral,
20 subcutaneous, intramuscular or intravenous routes at much higher daily doses
ranging from 1 to 60 mg.

36 A method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost according to claim 35, wherein said implants releases 50 – 100 μg of its hormonal compositions to the breast for extended periods of one to five years from one such implant by diffusion and biodegradation that saturates the said drug's binding sites in the breast and breast cancer to exert its maximum tumor control activity.

37 A method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost of claim 35, wherein said implants comprising of anti-estrogen and hormonally effective compositions selected from the anti-estrogen groups consisting of tamoxifen, raloxifene and toremifene, and from the hormonal groups consisting of progesterones, fluoxymesterone, corticosteroids and iodoestradiol.

38 A method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost according to claims 35, wherein breast implants of said drug compositions are made as single drug formulation from any one of the drugs from a group consisting of tamoxifen, raloxifene and toremifene, or from the hormonal group consisting of progesterones, fluoxymesterone, iodoestradiol, or two drug combinations one comprising of an anti-estrogen from the group of tamoxifen, raloxifene and toremifene, another comprising from the hormonal groups consisting of progesterones, prednisolone, fluoxymesterone, iodoestradiol, or as synergetic three drugs combinations as one from the group of

anti-estrogens such as tamoxifen, raloxifene and toremifene, another from the group of progesterones and a third from the group of prednisolone, fluoxymesterone, iodoestradiol.

- 5 39 The method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost of claim 35, wherein said breast implants are made as biodegradable fused combinations of said therapeutic drug compositions and a lipid carrier and said fused implants containing a single or multiples of said drug formulations for their slow release at a rate of 50 – 100 µg direct to the breast and to breast cancer
- 10 for one to five years from one such implant for to inhibit hormone dependent tumor growth and to minimize the systemic toxicity caused by administration of higher doses of said drugs by oral, subcutaneous, intramuscular or intravenous routs at much higher doses ranging from daily 1 to 60 mg to treat breast cancer.
- 15 40 A method for minimal or no toxic effects of hormonal treatment of breast cancer at much reduced cost with lesser toxicity according to claim 35, wherein said breast implants are made of Silastic capsules containing said drug composition as single drug formulation made from any one of the drugs from a group consisting of tamoxifen, raloxifene and toremifene, or from the hormonal group consisting
- 20 of progesterones, fluoxymesterone, iodoestradiol, or two drug combinations one comprising of an anti-estrogen from the group of tamoxifen, raloxifene and toremifene, another comprising from the hormonal group consisting of progesterones, prednisolone, fluoxymesterone, iodoestradiol, or as synergetic

three drugs combinations as one from the group of anti-estrogens such as tamoxifen, raloxifene and toremifene, another from the group of progesterones and a third from the group of prednisolone, fluoxymesterone, iodoestradiol for said formulation's slow release at a rate of 50-100 μ g direct to the breast and breast cancer for one to five years from one such implant for hormonal treatment of breast cancer.

41 A method for minimal or no toxic effects of hormonal treatment of breast cancer at much reduced cost of claim 35, wherein said breast implants are made as microcapsules prepared from biodegradable polymer and said microcapsules containing said therapeutic drug composition as single drug formulation made from any one of the drugs from a group consisting of tamoxifen, raloxifene and toremifene, or from the hormonal group consisting of progesterones, fluoxymesterone, iodoestradiol, or two drug combinations one comprising of an anti-estrogen from the group of tamoxifen, raloxifene and toremifene, another comprising from the hormonal group consisting of progesterones, prednisolone, fluoxymesterone, iodoestradiol, or as synergetic three drugs combinations as one from the group of anti-estrogens such as tamoxifen, raloxifene and toremifene, another from the group of progesterones and a third from the group of prednisolone, fluoxymesterone, iodoestradiol for said formulation's slow release at a rate of 50-100 μ g direct to the breast and breast cancer for one to five years from one such implant for hormonal treatment of breast cancer.

42 The method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost of claim 35, wherein said breast implants are made as injectable microcapsules prepared from biodegradable polymers and said microcapsules containing said therapeutic drug compositions dispensed in sterile liquid medium
5 in sterile syringe for direct injection to the breast and breast cancer for slow release of said drugs at a rate of 50-100 μg daily direct to the breast and breast cancer for one to five years from one such implant for hormonal treatment of breast cancer.

10 43 The method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost of claim 35, wherein said breast implants are made as injectable microcapsules prepared from biodegradable polymers and said microcapsules containing said therapeutic drug compositions are dispensed in a mixture of sterile liquid mediums like normal saline, a local anesthetic and ethanol in a
15 sterile syringe for direct injection to the breast and breast cancer as chelating slow release formulations of said drugs when in contact with breast tissue for the release of said drugs at a rate of 50-100 μg daily direct to the breast and breast cancer for one to five years from one such implant for hormonal treatment of breast cancer.

20

44 The method of minimal or no toxic hormonal treatment of breast cancer at much reduced cost of claim 35, wherein said breast implants are selected from readily available commercial pharmaceutical implant preparations made from any one of

the drugs from a group consisting of tamoxifen, raloxifene and toremifene, or from the hormonal group consisting of progesterones, fluoxymesterone, iodoestradiol, or two drug combinations one comprising of an anti-estrogen from the group of tamoxifen, raloxifene and toremifene, another comprising from the hormonal group consisting of progesterones, prednisolone, fluoxymesterone, iodoestradiol, or as synergetic three drugs combinations as one from the group of anti-estrogens such as tamoxifen, raloxifene and toremifene, another from the group of progesterones and a third from the group of prednisolone, fluoxymesterone, iodoestradiol for said formulation's slow release at a rate of 50-100 μg direct to the breast and breast cancer for one to five years from one such implant for hormonal treatment of breast cancer.

45 A method for minimal or no toxic effects from hormonal treatment of breast cancer at less than 5 percent cost of the present day hormone treatment of breast cancer when hormone treatment is combined with radiation therapy and to continue the hormone treatment after radiation for periods of one to five years by breast implants of hormone as single drug formulations from the drug group consisting of tamoxifen, raloxifene and toremifene, or from the hormone group consisting of progesterones, fluoxymesterone, iodoestradiol, or two drug combinations one comprising of an anti-estrogen from the group of tamoxifen, raloxifene and toremifene, another comprising from the hormonal group consisting of progesterones, prednisolone, fluoxymesterone, iodoestradiol, or as synergetic three drugs combinations as one from the group of anti-estrogens such

as tamoxifen, raloxifene and toremifene, another from the group of
progesterones and a third from the group of prednisolone, fluoxymesterone,
iodoestradiol for said formulation's slow release at a rate of 50-100 μ g direct to
the breast and breast cancer for one to five years from one such implant and
5 implanted before the start of radiation therapy for combined radiation and
hormone treatment of breast cancer and its continued hormonal treatment after
completion of radiation therapy for periods of one to five years with minimal
systemic toxicity from such hormone treatment of breast cancer as an alternative
to administration of said drugs by daily oral, subcutaneous, intramuscular or
10 intravenous routes at much higher doses ranging from 1 to 60 mg and to maintain
the cost of said implants preparations at less than 5 percent of the cost of present
day hormone treatment of breast cancer.

46 A method for minimal or no toxic hormone treatment of breast cancer at much
15 reduced cost according to claim 45, wherein hormone treatment is combined with
interstitial radiation therapy and said hormone is released directly to the breast
and breast cancer slowly at a daily rate of 50 – 100 μ g during the extended course
of interstitial radiation by interstitial radioactive seeds implants and thereafter for
periods of one to five years from one such implant and thereby minimizing the
20 systemic toxicity of hormone treatment of breast cancer as an alternative to
administration of said drugs by oral, subcutaneous, intramuscular or intravenous
routes at much higher doses ranging from 1 to 60 mg and higher and at less than 5
percent of the cost of present hormone treatment of breast cancer.

47 A method for minimal or no toxic hormone treatment of breast cancer at much
reduced cost according to claim 45, wherein hormone implant treatment
combined with interstitial radiation as a single procedure to minimize patient's
5 hospitalization and improve patient's comfort and said hormone is released
directly to the breast and breast cancer slowly at a daily rate of 50 – 100 μ g
during the course of external radiation and thereafter for periods of one to five
years from one such implant and thereby to minimizing the systemic toxicity of
hormone treatment of breast cancer as an alternative to daily administration of
10 said drugs by oral, subcutaneous, intramuscular or intravenous routes at much
higher doses ranging from 1 to 60 mg and which is less than 5 percent of the cost
of present day hormone treatment of breast cancer.

48 An implant method of hormones and their derivatives for treating hormone
15 dependent and hormone refractory breast cancer and its accessible metastasis for
tumor growth suppression at less than five percent of such treatments present
costs and said hormone implants selected as single drug formulations from the
group consisting of tamoxifen, raloxifene and toremifene, or from the hormone
group consisting of progestones, fluoxymesterone, iodoestradiol, or two drug
20 combinations one comprising of an anti-estrogen from the group of tamoxifen,
raloxifene and toremifene, another comprising from the hormonal group
consisting of progestones, prednisolone, fluoxymesterone, iodoestradiol, or as
synergetic three drugs combinations as one from the group of anti-estrogens such

as tamoxifen, raloxifene and toremifene, another from the group of
progesterones and a third from the group of prednisolone, fluoxymesterone,
iodoestradiol for said drug's slow release by biodegradation and diffusion at a
daily rate of 50-100 μ g for periods of one to five years from one such implant
and to saturate the receptor binding sites in tumor cells for such implanted
hormones to exert their cytotoxic activity for extended periods of one to five
years with minimal or no systemic toxicity as an alternative to daily
administration of said drugs by oral, subcutaneous, intramuscular or intravenous
routes at much higher daily doses ranging from 1 to 60 mg.

10

49 An implant method of hormones and their derivatives of claim 48 for continuous
daily treatment of hormone dependent and hormone refractory breast cancer and
its accessible metastasis for tumor growth suppression with hormones and their
derivatives at a daily dose of 50-100 μ g delivered directly to tumor for periods of
one to five years from one such implant by diffusion and biodegradation of
implanted compositions, implanting said compositions as single or synergetic
combination of hormones and their derivatives and said drugs are selected from
the anti-estrogen groups consisting of tamoxifen, raloxifene and toremifene and
from the hormonal groups consisting of iodo-estradiol, progesterones,
corticosteroids and they are fused with a lipoid carrier or encapsulated in Silastic
capsules or formulated as injectable microcapsules as suitable slow-release drug
compositions by biodegradation and diffusion as an alternative to daily
administration of said drugs by oral, subcutaneous, intramuscular or intravenous

15

20

routs at much higher daily doses ranging from 1 to 60 mg and at less than 5 percent of the cost of present day hormone treatment of breast cancer.

- 50 An implant method of hormones and its derivatives of claim 48 for continuous
5 daily treatment of hormone dependent and hormone refractory breast cancer and
its metastasis, wherein said implants providing effective tumor control by
continued saturation of hormone binding receptor sites in tumor with one or more
of such compositions and at a daily dose of 50-100 μ g delivered directly to tumor
for periods of one to five years from one such implant by diffusion and
10 biodegradation of said implanted compositions as an alternative to daily
administration of said drugs by oral, subcutaneous, intramuscular or intravenous
routs at much higher daily doses ranging from 1 to 60 mg with their associated
higher toxicity and over ninety five percent increased cost.
- 15 51 An implant method of hormones and their derivatives of claim 48 for continuous
daily treatment of hormone dependent and hormone refractory breast cancer and
its metastasis for one to five years periods, wherein said implants providing
effective tumor control by continued saturation of hormone binding receptor sites
in the tumor with one or more of such implanted compositions and said hormones
20 and their derivatives are directly delivered to the tumor at a daily dose of 50-100
 μ g for periods of one to five years from one such implant by diffusion and
biodegradation of said implanted compositions and combined with inhibition of
hypothalamic-pituitary LHRH, FSH and LH secretion by these composition's

systemic contents during such implant's effective period ranging from one to five years

5 18 Slow-release anti-cancer breast implants products for treatment of breast cancer and comprising of anti-estrogens and steroid hormones as fused with a lipoid carrier or as encapsulated in Silastic capsules or as injectable microcapsules and are suitable for breast implantation such that said hormonally and cytotoxically effective compositions are continuously released at relatively high constant rates to the breast.

10

19 The said products of claim 18 being further characterized by providing effective tumor control and having minimum or no systemic toxicity associated with said composition's breast implants than if they were daily administered orally for several years at much higher doses to achieve the same results.

15

20 Slow-release anti-cancer prostate implant product of claim 18, wherein said single drug formulation is made from any one of the anti-estrogen drugs from a group consisting of tamoxifen, raloxifene or toremifene and hormonal compositions consisting of progesterone, androgens or prednisolone.

20

21 Slow-release anti-cancer breast implant product of claim 18, wherein said synergetic two drugs formulations comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected

from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate or norgestrel or from the corticosteroids groups, the prednisolone.

5 22 Slow-release anti-cancer breast implant product of claim 18, wherein said synergetic three drugs formulations comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone.

10

23 Anti-cancer products of claim 18, wherein said compositions comprising of single or synergetic combination of hormonally and cytotoxically effective amount of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of
15 megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone as fused with a lipid carrier suitable for prostatic implantation.

20

24 Anticancer products according to claim 18, wherein said single or synergetic combination of hormonally and cytotoxically effective amounts of formulations as fused with a lipid carrier suitable for breast implantation such that said compositions are continuously released at relatively constant rates to the breast for longer periods and the contents of said compositions being kept in amounts

effective to suppress tumor growth with minimum or no systemic toxicity than if said drug compositions were administered daily by oral routes at much higher doses to achieve the same results as by said low dose breast implants.

5 26. Anticancer products according to claim 18, wherein said single or synergetic
combination of hormonally and cytotoxically effective formulations as in slow
release Silastic capsules suitable for breast implantation such that said
compositions are continuously released at relatively constant rates for longer
periods and with minimum or no systemic toxicity than if said drug compositions
10 were frequently administered orally at much higher doses to achieve the same
results as by said low dose breast implants.

27 Anticancer products according to claim 18, wherein said anti-cancer products
comprising of single or synergetic combination of hormonally and cytotoxically
15 effective amounts of an anti-estrogen from the groups of tamoxifen, raloxifene,
or toremifene and a progesterone composition selected from the group consisting
of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and
from the corticosteroids group prednisolone in same or separate slow release
injectable microcapsules suitable for breast implantation.

20

28 Anticancer products according to claim 27, wherein said single or synergetic
combination of hormonally and cytotoxically effective amount of formulations as
injectable microcapsules suitable for breast implantation such that said

compositions are continuously released at relatively constant rates and the contents of said compositions being kept in amounts effective to suppress tumor growth with minimum or no systemic toxicity than if said drug compositions were frequently administered orally at much higher doses to achieve the same results as by said low dose breast implants.

29 Anticancer products according to claim 18, wherein said implant products comprising of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof and fused with a lipoid carrier.

30 Anti-cancer prostatic implant products according to claim 18, wherein said biodegradable breast implants comprising of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof as injectable microcapsules.

31 Anti-cancer prostatic implant products of claim 18, wherein said breast implants comprises of an anti-estrogen from the groups of tamoxifen, raloxifene, or

toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and are made as separate or as mixtures of two or more thereof in Silastic capsules.

5

32 A slow-release hormonal breast implant method and products comprising single or synergetic combination of hormonally and cytotoxically effective compositions selected from the an anti-estrogen groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone and they are fused with a lipoid carrier or encapsulated in Silastic capsules or formulated as injectable microcapsules as suitable slow-release breast implantation and implanting said products for the treatment of early and advanced stage breast cancers and as hormonal treatment combined with radiation.

10

15

52 Anti-cancer products of claim 18, wherein said single or synergetic combinations of hormonally and cytotoxically effective amounts of an anti-estrogen from the groups of tamoxifen, raloxifene, or toremifene and a progesterone composition selected from the group consisting of megestrol acetate, medroxyprogesterone, norethindrone acetate norgestrel and from the corticosteroids group prednisolone in same or separate slow release Silastic capsules suitable for breast implantation.

20

53 Slow release hormonal breast implant method and products of claim 32, wherein
said one hormonal implant preparation delivers hormone treatment of breast
cancer for one to five years and for said one to five years hormone treatment
costing only about one thousand dollars as compared to the present day cost of
5 about 20-35,000 dollars for similar five years treatment with said hormones and
their derivatives by oral, subcutaneous, intramuscular or intravenous routes at
much higher daily doses ranging from 1 to 60 mg to treat breast cancer for
similar five years and hence less systemic toxicity than by administration of said
drugs at such high doses.

10

54 A method and product of claim 32, wherein said slow-release anti-estrogen
implant treatment to the breast as chemoprevention of breast cancer with lesser
cost and toxicity than those reported before.

15

20